Signal
Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve in a couple of weeks.
Evidence first: scan the strongest sources, then decide whether to go deeper.
Published 2026-03-09 11:07 UTCUpdated 2026-03-09 11:41 UTC
rss
fierce_biotech
Source links open
Source links and full evidence are open here. Archive history, compare-over-time, alerts, exports, API, integrations, and workflow are paid.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Alfasigma licenses liver drug from GSK in $590m deal Phil.Taylor Mon, 09/03/2026 - 11:41.
Score total
0.98
Momentum 24h
2
Posts
2
Origins
2
Source types
1
Duplicate ratio
0%
All evidence
All evidence
Alfasigma licenses liver drug from GSK in $590m deal
pharmaphorum · pharmaphorum.com · 2026-03-09 11:41 UTC
Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve in a couple of weeks.
Fierce Biotech · fiercebiotech.com · 2026-03-09 11:07 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 2Origin domains: 2Duplicates: -
Showing 2 / 0
Top publishers (this list)
- pharmaphorum (1)
- Fierce Biotech (1)
Top origin domains (this list)
- pharmaphorum.com (1)
- fiercebiotech.com (1)